Related Experiment Videos
Kawasaki disease
1Department of Cardiology, Children's Hospital, Boston, MA 02115, USA.
Insights
Kawasaki disease, a vasculitis affecting children, can lead to coronary artery aneurysms. Early treatment with intravenous gamma globulin significantly reduces this risk, but long-term monitoring is crucial for all patients.
Area of Science:
- Pediatric Cardiology
- Rheumatology
- Immunology
Background:
- Kawasaki disease is a primary cause of acquired heart disease in U.S. children.
- It is an acute vasculitis of unknown origin, primarily affecting young children.
- Coronary artery aneurysms affect 15-25% of affected children.
Purpose of the Study:
- To review the impact of Kawasaki disease on pediatric coronary arteries.
- To discuss the efficacy of intravenous gamma globulin in preventing coronary artery abnormalities.
- To outline the long-term management and surveillance strategies for affected children.
Main Methods:
- Review of existing literature on Kawasaki disease and its cardiovascular sequelae.
- Analysis of treatment outcomes, particularly the role of intravenous gamma globulin.
- Discussion of diagnostic and interventional approaches for coronary artery complications.
Main Results:
- Intravenous gamma globulin treatment in the acute phase decreases the risk of coronary artery aneurysms by 3-5 times.
- Half of aneurysmal segments show angiographic resolution but retain histologic and functional deficits.
- Giant aneurysms (>8 mm) carry the worst prognosis due to thrombosis risk.
Conclusions:
- Early intravenous gamma globulin administration is critical for mitigating coronary artery damage in Kawasaki disease.
- Ongoing surveillance, including stress tests and imaging, is essential for managing coronary artery disease.
- Long-term follow-up is necessary to understand the natural history of Kawasaki disease and its vascular impact.
Abstract:
Kawasaki disease is a leading cause of acquired heart disease in children in the USA. An acute vasculitis of unknown etiology, it occurs predominantly in infancy and early childhood, and more rarely in teenagers. Coronary artery aneurysms or ectasia develop in approximately 15-25% of children with the disease. Treatment with intravenous gamma globulin, 2 g per kg, in the acute phase reduces this risk three- to fivefold. Angiographic resolution occurs in approximately one-half of aneurysmal arterial segments, but these show persistent histologic and functional abnormalities. The remainder continue to be aneurysmal, often with development of progressive stenosis or occlusion. The worst prognosis occurs in children with so-called 'giant aneurysms', i.e. those with a maximum diameter greater than 8 mm, because thrombosis is promoted both by sluggish blood flow within the massively dilated vascular space and by the frequent development of stenotic lesions. Serial stress tests with myocardial imaging are mandatory in the management of patients with Kawasaki disease and significant coronary artery disease to determine the need for coronary angiography and transcatheter interventions or coronary bypass surgery. Continued long-term surveillance in patients with and without detected coronary abnormalities is necessary to determine the natural history of Kawasaki disease.